In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Timothy Wilkin from the University of California San Diego about the human papillomavirus (HPV) and anal cancer with options for screening, prevention, and vaccination.

They provide an overview of HPV and the types of HPV that lead to cancer. They discuss screening and prevention for anal cancer at HIV and PrEP clinics. They also discuss the findings of the ANCHOR study that demonstrated that high-resolution anoscopy screening detects and prevents anal cancer caused by HPV. Finally, they review HPV vaccination, its effectiveness, and the challenges with uptake of the vaccine in the population at large.

0:00 – Introduction

1:32 – Overview of HPV

3:01 – HPV and cancer

4:43 – Screening and prevention for anal cancer at HIV and PrEP clinics

9:38 – Findings of the ANCHOR study – efficacy of high resolution anoscopy in detecting anal cancer caused by HPV.

11:32 – Barriers to screening and treatment

15:05 – HPV vaccination - recommendations and efficacy

18:10 – Challenges with HPV vaccination uptake

24:30 – Next ten years of HPV and closing remarks

Resources and articles:

Single dose HPV vaccine article
https://pubmed.ncbi.nlm.nih.gov/35693874/

ANCHOR trial
https://pubmed.ncbi.nlm.nih.gov/35704479/

CDC OI HPV guidelines
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human

International Anal Neoplasia Society (guidelines and HRA training)
https://www.iansoc.org

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Paul Volberding from the University of California San Francisco about long COVID and new long COVID disability guidelines. They discuss the symptoms and causes of long COVID and where to find treatment. Dr Volberding discussed his work with the National Academy of Medicine, which recently released a report on long COVID disability guidelines.

0:00 – Introduction

1:53 – What is long COVID? How does someone know if they have it?

6:22 – Risk factors and causes of long COVID

11:51 – Treatments for and research on long COVID

14:14 – When is long COVID a disability? Disability recommendations from the National Academy of Medicine on long COVID

19:53 – How does someone with long COVID get help?

23:54 - Closing Remarks

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Peter Chin-Hong from the University of California San Francisco to get an update on important emerging infections. They discuss the current outbreak of COVID-19 and trends in the epidemiology of the disease. They also address emerging measles cases and the underlying pathophysiology of the disease. They also discuss the impact of vaccine disinformation on the risk of measles transmissibility. Finally, they address emerging infections such as avian flu, vaccine developments, and address others like respiratory syncytial virus (RSV) and pertussis.

0:00 – Introduction

1:42 – Status of the current COVID-19 outbreak

3:48 – Update on treatments and vaccination for COVID-19

11:53 – Overview of measles and transmissibility

15:30 – Measles herd immunity and vaccine disinformation

19:50 – Other emerging infections and vaccine developments

23:21 – Closing thoughts

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Raphael Landovitz from the UCLA Medical School about the latest information on HIV prevention via Preexposure Prophylaxis, or PrEP. They discuss the history of PrEP and early efficacy and then move into a discussion of the evolution of PrEP from episodic dosing to longer-acting therapies. The episode also highlights recent research and how that may impact the future of PrEP dosing.

0:00 - Introduction

1:59 - History of Preexposure Prophylaxis, or PrEP

5:39 - Why initial PrEP regimens were not 100% effective

12:01 - Discussion of episodic PrEP and 2-1-1 regimens

16:22 - How longer-acting therapy has been shown to be superior to episodic dosing

20:29 - LEVI syndrome - what is it?

25:05 - What the future holds for PrEP

29:18 - Closing Remarks

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

Episode 20 - The Impact of GLP-1 Receptor Agonists with Dr Suman Srinivasa

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Suman Srinivasa from Harvard Medical School about the impact of GLP-1 receptor agonists on diabetes and obesity. They discuss the mechanisms, benefits, and current and potential applications, including their use by people with HIV. The episode also highlights future prospects and challenges, including access to medication.

00:00 Introduction

01:42 Understanding GLP-1 Receptor Agonists

03:19 Mechanisms and Benefits of GLP-1 Receptor Agonists

05:34 Clinical Applications and Insurance Challenges

09:56 GLP-1 Receptor Agonists in HIV Patients

15:50 Future Prospects and Broader Applications

23:37 Closing Remarks

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," which is a panel discussion held on June 11, 2024.

Dr Paul A. Volberding from the University of California San Francisco serves as moderator and welcomes three distinguished panelists: Dr Carlos del Rio from Emory University, Yvonne Maldonado from Stanford University, and Dr Peter Chin-Hong from the University of California San Francisco. The episode covers various pressing topics, including updates on COVID-19, avian flu, MPOX, measles, and other viral diseases. Discussions touch on vaccines, their effectiveness, public health approaches, and current research.

00:00 Introduction to Going Antiviral Podcast

01:21 COVID-19 Current Issues and Personal Experiences

06:11 Long COVID and Paxlovid Study

07:59 Global Perspective on COVID-19

13:59 COVID-19 Vaccination Updates

23:52 Avian Flu: Current Concerns and Insights

29:15 The Threat of Avian Flu

29:46 Understanding H5N2 and Its Impact

33:09 The Ongoing MPOX Outbreak

37:02 Global Public Health Challenges

49:51 Travel Vaccines and Precautions

56:31 The Importance of RSV Vaccination

58:14 Concluding Remarks and Resources

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

Episode 18 - CROI 2024 Insights: Future Prospects of HIV Management and Cardiovascular Health with Dr Todd Brown Recorded May 3, 2024

This episode discusses the evolving landscape of HIV-related metabolic complications and cardiovascular health. Dr Michael Saag and Dr Todd Brown cover insights from CROI 2024, key studies on blood pressure management, the cardiovascular benefits of statins, and the promising role of GLP-1 receptor agonists in treating diabetes, obesity, and cardiovascular disease in people with HIV.

00:00 Introduction

01:56 Blood Pressure Management in HIV

09:56 The Impact of Statins on Cardiovascular Health

18:07 The Revolutionary Role of GLP-1 Receptor Agonists in HIV Management

27:01 Looking Ahead: The Future of HIV Treatment and Management

29:21 Closing Remarks and Future Directions

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...

Episode 17 - CROI 2024 Insights: Progress and Challenges in HIV Antiretroviral Therapy with Dr Barbara Taylor Recorded May 2, 2024

This episode of Going anti-Viral with Dr Michael Saag hosts Dr Barbara Taylor. They discussed topics covered at CROI 2024, including the 95-95-95 goal, long-acting antiretroviral therapies, mental health challenges in HIV care, and the potential for long-acting treatments in other viral diseases like hepatitis C.

00:00 Introduction and Remembering Dr Scott M. Hammer

00:27 CROI 2024 Highlights

02:55 Exploring the 95-95-95 Goal and Challenges in HIV Epidemic Control

09:01 Innovations in Long-Acting Antiretroviral Therapies

14:11 Advancements in Hepatitis C and B Therapies

16:51 COVID-19 Treatments and Resistance Concerns

19:26 Addressing Mental Health in HIV Care

__________________________________________________

Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.

Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.

Follow Going anti-Viral on:
Apple Podcasts
YouTube
Instagram
TikTok
...